Primary myelofibrosis has an annual incidence of 0.5-1.5 cases per 100,000 individuals in the United States. This annual range shifts to 0.1 to 1 case per 100,000 individuals in Europe. Adults aged 50 years or above are more prone to developing the condition. As a result, finding effective treatment alternatives is a key area of interest amongst the leading institutes and healthcare companies.
The Myelofibrosis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into myelofibrosis clinical trials. It covers various aspects related to the details of each of these drugs under development for Myelofibrosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The myelofibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from myelofibrosis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing myelofibrosis product development activities related to myelofibrosis.
Myelofibrosis is a rare blood disorder that scars the bone marrow tissue and results in disruption the production of blood cells in the body. Enlarged spleen is one of the major repercussions of the disease. It also reduces the platelet quantity, posing a risk of bleeding. Myelofibrosis can be categorised into primary and secondary. Primary myelofibrosis happens on its own while secondary myelofibrosis is associated with other bone marrow disorders. It is diagnosed via physical exams, bone marrow examinations, blood tests and others.
Treatments depend on the symptoms. For managing anemia, blood transfusions, along with Thalidomide and related drugs are advised, whereas targeted drug therapies, chemotherapy and splenectomy (surgical removal of the spleen) are advised for treating an enlarged spleen. With the increasing use of technologies such as artificial intelligence and machine learning in drug designing and development, the drug pipeline for myelofibrosis is promising and has multiple potent candidates.
This section of the report covers the analysis of Myelofibrosis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s myelofibrosis therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for myelofibrosis. There are around 277 drugs in phase II of myelofibrosis drugs.
The drug molecule categories covered under myelofibrosis pipeline analysis include JAK inhibitors, immunomodulatory drugs (IMiDs), androgens, and erythropoiesis-stimulating agents (ESAs). The choice of treatment depends on multiple factors including severity of the disease, patient profile and response to medications.
The EMR report for the myelofibrosis drug insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in myelofibrosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for myelofibrosis . It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of myelofibrosis drug candidates.
Sponsored by Novartis Pharmaceuticals, INC424 is in Phase 3 of an open label, multicenter study with over 2000 enrolled participants. The drug is under evaluation for its safety against treating primary myelofibrosis, post polycythemia myelofibrosis or post-essential thrombocythemia myelofibrosis in patients who have received prior treatment with available medications.
This drug is under investigation to treat patients with myelofibrosis with myeloid metaplasia (MMM). It is in Phase 2 of a prospective, randomized, multicenter, double-blind, active-control, parallel-group study sponsored by Celgene.
The myelofibrosis drug candidate 9-ING-41 is in a Phase 2 study to evaluate its anti-cancer clinical activity against treating advanced myelofibrosis. Developed by Actuate Therapeutics Inc., it is an intravenous maleimide-based, small molecule, potent selective GSK-3β inhibitor that is being studied in over 90 patients.
Currently, in Phase 1 of a multi-center, open-label, dose-escalation study, PIM447 is under investigation to be used as a combination therapy with Ruxolitinib and LEE011. Each regimen will be examined for its safety, efficacy, tolerability, pharmacodynamic effects, as well as spleen activity.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Myelofibrosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for myelofibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into myelofibrosis collaborations, regulatory environments, and potential growth opportunities within myelofibrosis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share